Regardless of World Health Organization (WHO) pathological type or Masaoka stage, patients with myasthenia gravis (MG) with a thymoma (a thymus tumor) experience significantly higher risks of clinical deterioration after thymectomy (thymus removal surgery) and a greater likelihood of progressing from ocular MG to generalized MG, according to a recent study published in BMC Medicine.
While some prior studies have linked thymomas in MG to worse recovery or higher generalization rates, others found no difference or suggested thymic hyperplasia (an enlarged thymus gland) as a risk factor.
Learn more about MG treatment and care
The authors aimed to resolve ongoing controversies about whether thymic pathology influences prognosis in patients with MG by conducting a large-scale, multicenter retrospective analysis comparing thymomatous and non-thymomatous cases, while also exploring subgroups by WHO pathological type and Masaoka stage across multiple outcomes, including postoperative deterioration, minimal manifestation status and conversion from ocular to generalized disease.
The study retrospectively analyzed around 1,250 patients with MG who underwent thymectomy, dividing them into thymomatous and nonthymomatous groups. The primary outcome was postoperative deterioration, with secondary outcomes including one-year minimal manifestation status and two-year ocular-to-generalized conversion.
Key findings confirmed higher deterioration risk and conversion in thymomatous cases, but no difference in minimal manifestation status or subgroup effects by WHO type/Masaoka stage.
“Our large-sample, multicenter study provides robust support for previous reports indicating that thymomas significantly increase the risk of post-thymectomy deterioration and generalization in patients with MG,” wrote the study’s authors. “However, regarding short-term post-thymectomy MMS rate, our findings revealed no significant difference between the thymomatous and nonthymomatous groups.”
Limitations of the study include the retrospective design, incomplete follow-up data leading to case exclusions, a short-term focus for some outcomes and the exclusion of thymic carcinoma. Future improvements could involve prospective multicenter trials, longer follow-up periods, standardized data collection and broader inclusion criteria.
Sign up here to get the latest news, perspectives, and information about MG sent directly to your inbox. Registration is free and only takes a minute.
